Where is StemoniX located?

StemoniX is headquartered in San Diego, United States.

How many employees does StemoniX have?

As of May 31, 2026, the latest employee count at StemoniX is 3.

Is StemoniX a funded company?

StemoniX is a funded company, having raised a total of $33.7M across 12 funding rounds to date. The company's 1st funding round was a $***** Seed round.

When was the latest funding round of StemoniX?

StemoniX's latest funding was a $***** Series B round on May 04, 2020, with participation from 0 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $1.23B in funding in 2026 to date.

Where does StemoniX rank among its competitors?

StemoniX ranks 7th amongst 118 active competitors, of which 17 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Cavalry Biosciences, which secured $275K in Jan, 2025.

Who are the top competitors of StemoniX?

StemoniX's top competitors include HitGen, Slingshot Bioscience and InterAx Biotech. Among them, Cavalry Biosciences secured the most recent funding round in January, 2025.

StemoniX - 2026 Company Profile, Funding & Competitors

StemoniX is an acquired company based in San Diego (United States), founded in 2014. It operates as an Engineering human brain and nerve models for neurological insights. StemoniX has raised $33.7M in funding from investors like Brightstone Venture Capital, Gopher Angels and EvoNexus. The company has 118 active competitors, including 17 funded and 9 that have exited. Its top competitors include companies like HitGen, Slingshot Bioscience and InterAx Biotech.

Company Details

Engineering human brain and nerve models for neurological insights, this company integrates tissue engineering, neural interfacing, and Artificial Intelligence to create reproducible brain organoids. These models offer reliable central and peripheral nervous system safety assessments. The company provides technology, products, and services focused on CNS-3D and PNS-3D applications. They offer engineered brain and peripheral nerve models for functional human insights, predicting human neurological response. Resources include a library, application notes, scientific posters, webinars, publications, protocols, and FAQs. This is a B2B tech company focused on CNS safety assessment.

Website: stemonix.com
Part Of

Key Metrics

Founded Year

2014

Location

San Diego, United States

Stage

Acquired

Total Funding

$33.7M in 12 rounds

Latest Funding Round

Series B, May 04, 2020, $*****

Investors

Brightstone Venture Capital & 20 more

Ranked

7^th among 118 active competitors

Employee Count

3 as on May 31, 2026

Similar Companies

HitGen & 120 more

Exit Details

Acquired by Cancer Genetics (Aug 24, 2020)

View StemoniX's full profile

StemoniX got acquired by Cancer Genetics on Aug 24, 2020.

Click here to take a look at StemoniX's acquisition in detail

StemoniX has raised a total funding of $33.7M over 12 rounds. StemoniX has 21 institutional investors.

Here is the list of recent funding rounds of StemoniX:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 04, 2020	2089943	Series B	1635529	7758415	6895004	2578053
Oct 11, 2019	6675723	Series B	8926232	5041242	6653323	1876361
Feb 28, 2019	5159282	Series B	6604514	9253828	Brightstone Venture Capital	Seed San Diego & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of StemoniX's funding rounds and investors

StemoniX's employee count trend

StemoniX has 3 employees as of May 26. Here is StemoniX's employee count trend over the years:

Uncover StemoniX's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of StemoniX include HitGen, Slingshot Bioscience and InterAx Biotech. Here is the list of Top 10 competitors of StemoniX, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	HitGen 2012, Lanzhou (China), Public	Developer of DNA encoded libraries for drug discovery	$39.1M	CDH, Shiyu & 2 others	58/100
2nd	Slingshot Bioscience 2012, Berkeley (United States), Series A	Developer of next-generation synthetic cells for diagnostics and therapeutics	$46.4M	Northpond Ventures, Arch Venture Partners ... & 2 others	56/100
3rd	InterAx Biotech 2016, Villigen (Switzerland), Series A	Arrestin-based biosensors and computational methods for GPCR based drug discovery	$3.19M	Verve Ventures, Venture Kick & 6 others	54/100
4th	Passkey Therapeutics 2022, Cambridge (United States), Unfunded	Developer of multifunctional therapeutics targeting rare combinations of proteins	-	-	49/100
5th	Vectus Biosystems 2005, Rosebery (Australia), Public	Develops drug discovery platform	-	-	45/100
6th	Sequence Bio 2013, St John s (Canada), Seed	Sequence Bio is a Newfoundland and Labrador biotechnology company striving to improve how we treat diseases and develop medicines.	$5.47M	DCVC, Y Combinator & 5 others	45/100
7th	StemoniX 2014, San Diego (United States), Acquired	Engineering human brain and nerve models for neurological insights	$33.7M	For Good Ventures, Mayo Clinic Business Accelerator ... & 19 others	44/100
8th	Cavalry Biosciences 2021, San Francisco (United States), Series A	Developer of therapeutics to treat chronic and rare diseases	-	Mission BioCapital, Venrock & 2 others	43/100
9th	Aucta Pharmaceuticals 2012, New Brunswick (United States), Seed	Innovating enhanced therapeutics using technology for specialty brand and generic products	-	Shanghai Changjiang Guohong Investment Management, SDIC Venture Capital Management ... & 3 others	42/100
10th	Signal Pharmaceuticals 1993, San Diego (United States), Acquired	Discoverer of drugs to regulate disease-related genes	$12M	Kleiner Perkins, The Vertical Group & 10 others	40/100